-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Ginkgo Bioworks (NYSE:DNA) Shares Gap Up to $3.17
Ginkgo Bioworks (NYSE:DNA) Shares Gap Up to $3.17
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA – Get Rating)'s share price gapped up before the market opened on Tuesday . The stock had previously closed at $3.17, but opened at $3.28. Ginkgo Bioworks shares last traded at $3.24, with a volume of 339,500 shares.
Analysts Set New Price Targets
A number of research firms have issued reports on DNA. Raymond James increased their target price on shares of Ginkgo Bioworks from $11.50 to $14.50 and gave the stock an "outperform" rating in a report on Tuesday, August 16th. Bank of America lowered shares of Ginkgo Bioworks from a "neutral" rating to an "underperform" rating and set a $3.00 target price on the stock. in a report on Wednesday, May 18th. BTIG Research increased their target price on shares of Ginkgo Bioworks from $5.00 to $6.00 and gave the stock a "buy" rating in a report on Tuesday, August 16th. Finally, Jefferies Financial Group dropped their price objective on shares of Ginkgo Bioworks from $11.50 to $4.35 in a research report on Thursday, June 16th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, Ginkgo Bioworks presently has a consensus rating of "Moderate Buy" and an average target price of $8.69.
Get Ginkgo Bioworks alerts:Ginkgo Bioworks Price Performance
The company has a debt-to-equity ratio of 0.03, a quick ratio of 11.78 and a current ratio of 11.84. The company has a market capitalization of $5.48 billion, a PE ratio of -1.57 and a beta of 1.84. The company's 50-day simple moving average is $2.98 and its 200-day simple moving average is $3.10.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently bought and sold shares of the business. Lincoln National Corp acquired a new stake in shares of Ginkgo Bioworks in the 2nd quarter worth $26,000. Atria Wealth Solutions Inc. acquired a new stake in shares of Ginkgo Bioworks in the 2nd quarter worth $30,000. Cetera Investment Advisers acquired a new stake in shares of Ginkgo Bioworks in the 2nd quarter worth $33,000. First Horizon Advisors Inc. acquired a new stake in shares of Ginkgo Bioworks in the 2nd quarter worth $38,000. Finally, Endurance Wealth Management Inc. lifted its stake in shares of Ginkgo Bioworks by 100.0% in the 1st quarter. Endurance Wealth Management Inc. now owns 10,000 shares of the company's stock worth $40,000 after acquiring an additional 5,000 shares during the period. 53.37% of the stock is owned by hedge funds and other institutional investors.About Ginkgo Bioworks
(Get Rating)
Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals.
Featured Stories
- Get a free copy of the StockNews.com research report on Ginkgo Bioworks (DNA)
- Is This Medical Gear Maker Ready To Continue Its Rally?
- The Five (5) Hottest Stocks To Watch Ahead Of Q3 Earnings
- Has Take-Two Interactive Devolved into a One-Trick Pony?
- Four Cheap Stocks With Interesting Insider Activity
- Can Health Drink Maker Celsius Outrun Its Monster Rival?
Receive News & Ratings for Ginkgo Bioworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ginkgo Bioworks and related companies with MarketBeat.com's FREE daily email newsletter.
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA – Get Rating)'s share price gapped up before the market opened on Tuesday . The stock had previously closed at $3.17, but opened at $3.28. Ginkgo Bioworks shares last traded at $3.24, with a volume of 339,500 shares.
Ginkgo Bioworks Holdings，Inc.(紐約證券交易所代碼：DNA-GET Rating)的股價在週二開盤前大幅上漲。該股之前的收盤價為3.17美元，但開盤時為3.28美元。銀杏生物控股公司的股票最後交易價格為3.24美元，成交量為33.95萬股。
Analysts Set New Price Targets
分析師設定新的價格目標
A number of research firms have issued reports on DNA. Raymond James increased their target price on shares of Ginkgo Bioworks from $11.50 to $14.50 and gave the stock an "outperform" rating in a report on Tuesday, August 16th. Bank of America lowered shares of Ginkgo Bioworks from a "neutral" rating to an "underperform" rating and set a $3.00 target price on the stock. in a report on Wednesday, May 18th. BTIG Research increased their target price on shares of Ginkgo Bioworks from $5.00 to $6.00 and gave the stock a "buy" rating in a report on Tuesday, August 16th. Finally, Jefferies Financial Group dropped their price objective on shares of Ginkgo Bioworks from $11.50 to $4.35 in a research report on Thursday, June 16th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, Ginkgo Bioworks presently has a consensus rating of "Moderate Buy" and an average target price of $8.69.
一些研究公司已經發布了關於DNA的報告。雷蒙德·詹姆斯在8月16日(星期二)的一份報告中將銀杏生物工場的股票目標價從11.50美元上調至14.50美元，並給予該股“跑贏大盤”的評級。美國銀行將Ginkgo Bioworks的股票評級從中性下調至表現不佳，併為該股設定了3.00美元的目標價。在5月18日星期三的一份報告中。BTIG Research在8月16日(星期二)的一份報告中將銀杏生物工場股票的目標價從5.00美元上調至6.00美元，並給予該股“買入”評級。最後，傑富瑞金融集團在6月16日星期四的一份研究報告中將銀杏生物的股票目標價從11.50美元下調至4.35美元。一位研究分析師對該股的評級為賣出，一位分析師給出了持有評級，六位分析師給出了該公司的買入評級。根據MarketBeat.com的數據，銀杏生物目前的共識評級為“中等買入”，平均目標價為8.69美元。
Ginkgo Bioworks Price Performance
銀杏生物工場性價比
The company has a debt-to-equity ratio of 0.03, a quick ratio of 11.78 and a current ratio of 11.84. The company has a market capitalization of $5.48 billion, a PE ratio of -1.57 and a beta of 1.84. The company's 50-day simple moving average is $2.98 and its 200-day simple moving average is $3.10.
該公司的負債權益比率為0.03，速動比率為11.78，流動比率為11.84。該公司市值為54.8億美元，市盈率為-1.57，貝塔係數為1.84。該公司的50日簡單移動均線切入位在2.98美元，200日簡單移動均線切入位在3.10美元。
Institutional Inflows and Outflows
機構資金流入和流出
About Ginkgo Bioworks
關於銀杏生物工場
(Get Rating)
(獲取評級)
Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals.
銀杏生物工程控股公司及其子公司開發細胞編程平臺。它的平臺用於對細胞進行編程，以實現產品的生物生產，如新型療法、食品配料和從石油中提取的化學品。該公司服務於各種終端市場，包括特種化學品、農業、食品、消費品和藥品。
Featured Stories
專題報道
- Get a free copy of the StockNews.com research report on Ginkgo Bioworks (DNA)
- Is This Medical Gear Maker Ready To Continue Its Rally?
- The Five (5) Hottest Stocks To Watch Ahead Of Q3 Earnings
- Has Take-Two Interactive Devolved into a One-Trick Pony?
- Four Cheap Stocks With Interesting Insider Activity
- Can Health Drink Maker Celsius Outrun Its Monster Rival?
- 免費獲取StockNews.com關於銀杏生物工程(DNA)的研究報告
- 這家醫療設備製造商準備好繼續反彈了嗎？
- 第三季度財報公佈前最值得關注的五(5)只股票
- Take-Two Interactive是否已經退化為一招小馬？
- 具有有趣內幕活動的四隻廉價股票
- 健康飲料製造商Celsius能否超越其Monster競爭對手？
Receive News & Ratings for Ginkgo Bioworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ginkgo Bioworks and related companies with MarketBeat.com's FREE daily email newsletter.
接受《銀杏生物工場日報》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對銀杏生物工程和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧